Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Salute | Prodotti farmaceutici | 653,39 Bln ARS | 77,8x | 1,19 | 15.275 ARS | -5,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson & Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 372,19 Bln ARS | 25,3x | -0,46 | 11.700 ARS | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Salute | Prodotti farmaceutici | 372,19 Bln ARS | 25,3x | 1.340 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Johnson & Johnson | Buenos Aires | Salute | Prodotti farmaceutici | 370,03 Bln ARS | 25,3x | -1,32 | 815 ARS | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abbvie | Buenos Aires | Salute | Prodotti farmaceutici | 292,76 Bln ARS | 57,8x | -2,68 | 18.900 ARS | -4,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Merck & Co DRC | Buenos Aires | Salute | Prodotti farmaceutici | 243,79 Bln ARS | 20,2x | 0,12 | 21.950 ARS | -3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Novartis DRC | Buenos Aires | Salute | Prodotti farmaceutici | 205,38 Bln ARS | 11,9x | 0,13 | 29.275 ARS | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
AstraZeneca PLC | Buenos Aires | Salute | Prodotti farmaceutici | 194,10 Bln ARS | 29,9x | 3,07 | 35.950 ARS | -5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Amgen AR | Buenos Aires | Salute | Prodotti farmaceutici | 149,43 Bln ARS | 35,4x | -0,81 | 10.700 ARS | -5,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Pfizer DRC | Buenos Aires | Salute | Prodotti farmaceutici | 140,61 Bln ARS | 33,2x | -0,55 | 7.040 ARS | -7,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Salute | Prodotti farmaceutici | 114,89 Bln ARS | -15,8x | 0,08 | 21.200 ARS | -5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gilead Sciences | Buenos Aires | Salute | Prodotti farmaceutici | 110,18 Bln ARS | 877,8x | -8,96 | 25.150 ARS | -5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
GSK plc DRC | Buenos Aires | Salute | Prodotti farmaceutici | 67,58 Bln ARS | 21,2x | -0,36 | 9.530 ARS | -4,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cardinal Health | Buenos Aires | Salute | Prodotti farmaceutici | 28,97 Bln ARS | 22,7x | 0,04 | 45.225 ARS | -4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Biogen AR | Buenos Aires | Salute | Prodotti farmaceutici | 22,98 Bln ARS | 14,2x | 1,44 | 14.000 ARS | -4,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Laboratorios Richmond | Buenos Aires | Salute | Prodotti farmaceutici | 140,51 Mrd ARS | 8,2x | 0,02 | 1.740 ARS | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Inst rosembusc | Buenos Aires | Salute | Prodotti farmaceutici | 4,43 Mrd ARS | 4,3x | 0,01 | 104 ARS | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |